A 12-week Comparison of the Efficacy and Safety of Albuterol Spiromax Versus Placebo in Subjects 12 Years and Older With Persistent Asthma

Trial Profile

A 12-week Comparison of the Efficacy and Safety of Albuterol Spiromax Versus Placebo in Subjects 12 Years and Older With Persistent Asthma

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Jul 2015

At a glance

  • Drugs Salbutamol (Primary)
  • Indications Asthma
  • Focus Registrational; Therapeutic Use
  • Sponsors Teva Branded Pharmaceutical Products R&D
  • Most Recent Events

    • 01 Apr 2015 According to Teva Pharmaceutical Industries media release, company receives FDA approval for ProAir RespiClick (albuterol sulfate) for treatment and prevention of bronchospasm and exercise induced bronchospasm in patients 12 age and over.
    • 24 Dec 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 27 Sep 2013 Planned end date changed from 1 Sep 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top